Business Description
Revelation Biosciences Inc
NAICS : 541715
SIC : 2834
ISIN : US76135L7055
Share Class Description:
REVB: Ordinary SharesTotal Employee Number:
9Description
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.52 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 93.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 47.45 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.44 | |||||
9-Day RSI | 44.38 | |||||
14-Day RSI | 45.49 | |||||
3-1 Month Momentum % | 12.87 | |||||
6-1 Month Momentum % | -11.63 | |||||
12-1 Month Momentum % | -89.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.22 | |||||
Quick Ratio | 6.22 | |||||
Cash Ratio | 6.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -114.99 | |||||
ROA % | -93.68 | |||||
ROIC % | -2001.78 | |||||
3-Year ROIIC % | -81.29 | |||||
ROC (Joel Greenblatt) % | -2359.72 | |||||
ROCE % | -115.81 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.39 | |||||
Price-to-Tangible-Book | 0.39 | |||||
EV-to-EBIT | 0.6 | |||||
EV-to-EBITDA | 0.6 | |||||
EV-to-FCF | 0.71 | |||||
| Price-to-Net-Current-Asset-Value | 0.43 | |||||
| Price-to-Net-Cash | 0.44 | |||||
Earnings Yield (Greenblatt) % | 166.67 | |||||
FCF Yield % | -234.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:REVB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Revelation Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -12.31 | ||
| Beta | -0.3041 | ||
| 3-Year Sharpe Ratio | -2.91 | ||
| 3-Year Sortino Ratio | -2.28 | ||
| Volatility % | 55.78 | ||
| 14-Day RSI | 45.49 | ||
| 14-Day ATR ($) | 0.069657 | ||
| 20-Day SMA ($) | 1.05403 | ||
| 12-1 Month Momentum % | -89.89 | ||
| 52-Week Range ($) | 0.875 - 11.6 | ||
| Shares Outstanding (Mil) | 3.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revelation Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revelation Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 170 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 170 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 58 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 1.15 (+0.88%) | ||
| General meeting for 2026 | 2026-06-24 12:00 | 1.05 (+0.58%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.02 (+0.00%) | ||
| 38th Annual Roth Conference | 2026-03-24 14:00 | 1.22 (+2.52%) | ||
| Annual report for 2025 | 2026-02-26 | 1.41 (+6.82%) | ||
| 0.25:1 Stock Split | 2026-01-28 | 2.09 (+3.16%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 4.32 (-0.92%) |
Show
Entries
Revelation Biosciences Inc Frequently Asked Questions
What is Revelation Biosciences Inc(REVB)'s stock price today?
The current price of REVB is $1.01. The 52 week high of REVB is $11.60 and 52 week low is $0.88.
When is next earnings date of Revelation Biosciences Inc(REVB)?
The next earnings date of Revelation Biosciences Inc(REVB) is 2026-11-06 Est..
Does Revelation Biosciences Inc(REVB) pay dividends? If so, how much?
Revelation Biosciences Inc(REVB) does not pay dividend.
Press Release
Articles on Revelation Biosciences Inc
Revelation Biosciences (REVB) Partners with Avance Clinical for Phase 2/3 Titan Study on Acute Kidney Injury
Aug 19, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers